<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066612</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000316428</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S0306</secondary_id>
    <nct_id>NCT00066612</nct_id>
  </id_info>
  <brief_title>S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy</brief_title>
  <official_title>Phase II Study of Irinotecan in Patients With Advanced Transitional Cell Carcinoma of the Urothelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as irinotecan use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who&#xD;
      have recurrent or refractory advanced transitional cell cancer of the urothelium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the probability of response (confirmed complete and partial response) to&#xD;
           treatment with irinotecan in patients with recurrent or refractory advanced transitional&#xD;
           cell carcinoma of the urothelium previously treated with platinum-based chemotherapy.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the overall and progression-free survival of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prior pelvic&#xD;
      radiotherapy (yes vs no).&#xD;
&#xD;
      Patients receive irinotecan IV over 90 minutes on day 1. Courses repeat every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 5-10&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of response (confirmed complete and partial response)</measure>
    <time_frame>From date of registration to date of progression or death from any cause, whichever came first, assessed up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and grade of adverse events</measure>
    <time_frame>From date of registration to date of progression or death from any cause, whichever came first, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of registration to date of progression or death from any cause, whichever came first, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of registration to date of progression or death from any cause, whichever came first, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Urethral Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Irinotecan will be given 250 mg/m^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed transitional cell carcinoma (TCC) of the urothelium,&#xD;
             including the bladder, renal pelvis, ureter, and urethra&#xD;
&#xD;
               -  Stage T2-4, N0-3, M1 OR stage T2-4, N+, M0, unresectable disease&#xD;
&#xD;
               -  The following additional histologic subtypes are eligible:&#xD;
&#xD;
                    -  Poorly differentiated TCC&#xD;
&#xD;
                    -  Predominant TCC with rare foci of squamous differentiation&#xD;
&#xD;
                    -  Predominant TCC with rare foci of adenocarcinoma&#xD;
&#xD;
               -  The following histologic subtypes are ineligible:&#xD;
&#xD;
                    -  Adenocarcinoma&#xD;
&#xD;
                    -  Small cell carcinoma&#xD;
&#xD;
                    -  Sarcoma&#xD;
&#xD;
                    -  Squamous cell carcinoma&#xD;
&#xD;
                    -  Mixed adeno/squamous/transitional histology&#xD;
&#xD;
          -  Incurable by surgery or radiotherapy&#xD;
&#xD;
          -  Progressed or recurred after 1, and only 1, prior cisplatin- or carboplatin-containing&#xD;
             systemic regimen for metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Soft tissue disease that has been irradiated within the past 2 months is not&#xD;
                  considered measurable disease&#xD;
&#xD;
          -  No uncontrolled central nervous system (CNS) metastases&#xD;
&#xD;
               -  CNS metastases that have responded to or stabilized after prior radiotherapy are&#xD;
                  allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,200/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (SGOT) less than 3 times ULN (5 times ULN if liver&#xD;
             metastases are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer that is currently in complete remission&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy&#xD;
&#xD;
          -  No prior topoisomerase I inhibitors (e.g., irinotecan or topotecan)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy to the pelvis&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  Prior adjuvant therapy allowed&#xD;
&#xD;
          -  At least 14 days since prior Hypericum perforatum (St. John's Wort)&#xD;
&#xD;
          -  More than 7 days since prior phenytoin, phenobarbital, carbamazepine, or any other&#xD;
             enzyme-inducing anticonvulsant drugs (EIACDs)&#xD;
&#xD;
          -  No St. John's Wort during and for 7 days after study participation&#xD;
&#xD;
          -  No concurrent EIACDs&#xD;
&#xD;
          -  No concurrent medications that cause myelosuppression&#xD;
&#xD;
          -  No concurrent medications that cause diarrhea&#xD;
&#xD;
          -  Concurrent gabapentin or other non-EIACDs are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz M. Beer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Beer TM, Goldman B, Nichols CR, Petrylak DP, Agarwal M, Ryan CW, Crawford ED; Southwest Oncology Group. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. Clin Genitourin Cancer. 2008 Mar;6(1):36-9.</citation>
    <PMID>18501081</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>recurrent transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>anterior urethral cancer</keyword>
  <keyword>posterior urethral cancer</keyword>
  <keyword>recurrent urethral cancer</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

